Skip to content
PeptideAgent

Peptides for irritable bowel syndrome: what the evidence shows

By the PeptideAgent Editorial Team. Draft, pending editorial review.  Last verified

At a glance

Linaclotide, a guanylate cyclase-C agonist peptide, is FDA approved for IBS with constipation; in phase 3 trials about 34% of patients met the combined pain and bowel movement endpoint versus 14% to 21% on placebo. It is not used for diarrhea predominant IBS. BPC-157 is marketed for gut symptoms but has no IBS data in people.

Evidence: Strongest: Human RCT evidence2 peptides gradedVerified: Verified Sep 27, 2026

Do peptides help with irritable bowel syndrome?

2 peptides are graded for irritable bowel syndrome on this page. The strongest grade is human RCT evidence, for linaclotide. Each one is weighed against the standard of care below, and the evidence table gives the grade and a note for every peptide.

What is the standard of care for irritable bowel syndrome?

Positive diagnosis with Rome IV criteria and limited testing; soluble fiber and a supervised low FODMAP diet trial; antispasmodics; linaclotide, plecanatide, or lubiprostone for IBS with constipation; rifaximin or eluxadoline for IBS with diarrhea; gut directed psychotherapy and low dose tricyclic antidepressants for pain.

Any peptide below should be judged against this baseline, not against doing nothing. Talk to a licensed provider before replacing or adding to an established treatment.

Which peptides have been studied for irritable bowel syndrome?

Ordered by strength of evidence for this use. Grades follow the methodology; each peptide page lists the individual studies.

Peptides studied for Irritable bowel syndrome with evidence grades
PeptideEvidence for this useNote
LinaclotideEvidence: Human RCT evidenceTwo phase 3 trials (about 800 patients each): combined responder rates 33.7% and 33.6% versus 13.9% and 21.0% on placebo; diarrhea is the main side effect; FDA approved as Linzess. [2] [3] [4]
BPC-157Evidence: Animal-only evidenceRodent gut injury models only; no human IBS study. [5]

Cost and access

Price ranges, lawful channels, and insurance notes for peptides graded here. State rules are in the legal guides by state.

Frequently asked questions

Which peptide has the strongest evidence for irritable bowel syndrome?

Linaclotide has the strongest evidence among the peptides graded here, at human RCT evidence. Two phase 3 trials (about 800 patients each): combined responder rates 33.7% and 33.6% versus 13.9% and 21.0% on placebo; diarrhea is the main side effect; FDA approved as Linzess. [2] [3] [4]

Is any peptide FDA approved for irritable bowel syndrome?

Linaclotide is an FDA approved drug, but an approval covers only the indications on that label, so check the label before assuming it applies to irritable bowel syndrome. The other peptides graded here are not FDA approved. [2] [3] [4] [6]

Has any peptide been tested in a randomized trial for irritable bowel syndrome?

Yes, for linaclotide. Check each note for the population and endpoints: a randomized trial in a related group or on a surrogate marker is weaker than one on the outcome you care about. [2] [3] [4]

From the blog

Sources

  1. [1]ACG clinical guideline: management of irritable bowel syndrome. Am J Gastroenterol 2021PubMed 33315591, 2021
  2. [2]Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safetyPubMed 22986437, 2012
  3. [3]A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipationPubMed 22986440, 2012
  4. [4]FDA prescribing information for Linzess (linaclotide) capsules, via DailyMedFDA, 2023
  5. [5]The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migrationPubMed 21030672, 2011
  6. [6]Drugs@FDA: FDA-approved drugs databaseFDA